Q.ANT Debuts First Interactive Live Demonstration and New Benchmarks for Analog Photonic Computing at ISC 2025
Stuttgart, Germany--(Newsfile Corp. - June 4, 2025) - Q.ANT, today announced it will showcase live demonstrations of its photonic Native Processing Server (NPS) at ISC 2025, a leading global conference for high-performance computing (HPC). For the first time, attendees will be able to interact directly with functional photonic computing, witnessing how light can drive breakthroughs in energy and computational efficiency for AI, Physics Simulations, and other complex scientific workloads.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
For the first time, ISC attendees can experience analog photonic computing in action
Q.ANT's Native Processing Server (NPS) can deliver breakthrough levels of performance and energy savings
Q.ANT showcases new benchmarks in high precision and efficiency for complex AI and scientific workloads
Click image above to view full announcement.
About Q.ANT
Q.ANT is a deep-tech company pioneering photonic computing. Founded in 2018, Q.ANT develops processors that compute natively with light--delivering scalable, energy-efficient performance for next-generation AI and HPC applications. The company operates a dedicated photonic chip pilot line in Stuttgart and is currently shipping its Native Processing Server to selected partners.
Contacts:
Toni Sottak +1 843 530 4442 toni@wiredislandpr.com
Edith Laga +49 157 830 407 51 edith.laga@qant.gmbh
Source: Q.ANT GmbH
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254441
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
41 minutes ago
- Bloomberg
Novo Climbs After FT Reports Activist Parvus Amassed Stake
Novo Nordisk A/S shares rose to the highest level in more than two months after a report that activist hedge fund Parvus Asset Management has built a stake as the Danish drugmaker struggles to keep its lead in the obesity market. The stock climbed as much as 2.5% in early Copenhagen trading.
Bloomberg
41 minutes ago
- Bloomberg
Euro Could Reach $1.40 Within Two Years: Macro Hive
Macro Hive CEO Bilal Hafeez says the euro could reach $1.40 within one or two years. "There has to be an outlet somewhere for dollar weakness," Hafeez tells Bloomberg Television. FX options show growing appetite for medium-term euro upside. Markets now see nearly a 1-in-2 chance of the single currency trading above $1.20 by the end of 2027, a far cry from a year ago where there was talk of parity. (Source: Bloomberg)
Yahoo
an hour ago
- Yahoo
Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value
UPPSALA, SE / / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers. Two of the three work orders were placed by the Tier-1 (revenues >10 BUSD) U.S. pharmaceutical company which recently entered into a broader service agreement with Biovica, including a record-breaking SEK 4 million work order. These latest orders will support the development of next-generation CDK4/6 inhibitors. The orders are a combination of retrospective analysis, that will be performed in the coming months, and prospective analysis that will be performed over ~2 years. "I'm pleased to see that our Pharma customers recognize the value of DiviTum® TKa and are returning for continued use. The reliable and meaningful data it provides continues to drive demand from leading pharmaceutical companies, who use it in the development of new cancer therapies that will benefit patients.," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica secures three new work orders in Pharma Services of 2,5 MSEK in value SOURCE: Biovica International View the original press release on ACCESS Newswire
